Background Resection is recommended for main duct intraductal papillary mucinous neoplasms (IPMNs) of the pancreas because of the high risk of malignancy, but the indications for resection of branch duct and mixed-type IPMNs remain controversial. Our objective was to determine the appropriate management of IPMNs based on clinicopathologic characteristics and survival data obtained after resection. Methods A total of 72 consecutive IPMN patients who underwent resection between January 1984 and June 2006 were reviewed. The lesions were classified as main duct, branch duct, or mixed-type IPMNs and histologically graded as noninvasive (adenoma, borderline neoplasm, carcinoma in situ) or invasive. Results Main duct IPMNs (n = 15) were associated with a significantly worse prognosis than other subtypes. For branch duct (n = 49) and mixed-type IPMNs (n = 8), the diameter of the cystic lesions was an independent predictor of malignancy by multivariate analysis. However, four patients with cysts \30 mm in diameter and no mural nodules had a malignancy. No patient with noninvasive IPMN died of this disease, showing excellent survival, whereas the 5-year survival rate of patients with invasive IPMNs was only 57.6% and was significantly worse than that of patients with noninvasive IPMNs (p = 0.0002). Conclusions Resection of all main duct IPMNs seems to be reasonable. Invasive IPMNs were associated with significantly worse survival than noninvasive IPMNs. Although the diameter of cystic lesions was a predictor of malignancy for branch duct and mixed-type IPMNs, precise preoperative identification of malignancy was difficult. Therefore, these lesions should be managed by aggressive resection before invasion occurs to improve survival.
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Intraductal papillary mucinous neoplasms (IPMNs) are intraductal mucin-producing neoplasms of the pancreas that cause cystic dilatation of the main and/or branch pancreatic ducts. This neoplasm was first described in 1982 by Ohashi et al. [1] as a mucin-producing tumor of the pancreas; and it was eventually recognized and defined clearly by the World Health Organization (WHO) in 1996 as an intraductal papillary mucinous tumor (IPMT) [2] . In the revised WHO classification published in 2000, IPMT was renamed IPMN [3] . Although IPMNs have been increasingly detected over the last decade, the natural history of this neoplasm is not fully understood, and its management remains controversial [4, 5] .
IPMNs are thought to have malignant potential and to undergo transformation from adenoma to borderline neoplasms, followed by carcinoma in situ (CIS), and finally invasive carcinoma, which is the classic adenoma-carcinoma sequence [4] . Complete resection of noninvasive IPMNs (CIS or earlier disease) has been reported to achieve excellent survival [6] [7] [8] . On the other hand, the survival rate after resection of invasive IPMNs has been reported to be markedly worse than that of patients without invasive components [6] [7] [8] . Although it is also unclear whether there is a difference of survival between invasive IPMN and pancreatic ductal carcinoma [7, 8] , there is general consensus that IPMNs with CIS or invasive carcinoma are potentially fatal diseases unless they are surgically resected [4] .
IPMNs can be divided into three subtypes-main duct, branch duct, mixed type-based on imaging findings and/ or histology [4, 5] . The frequency of malignancy and the survival rate after resection show differences that depend on the neoplasm subtype. Main duct IPMNs are usually malignant, with the malignancy rate ranging from 60% to 83% [6, [9] [10] [11] , whereas branch duct IPMNs have a relatively lower frequency of malignancy (6-46%) [6, 9, 10] .
The international consensus guidelines [5] recommend resection of all main duct IPMNs if the patient is a good surgical candidate because of the high frequency of malignancy. However, the indications for resection of branch duct IPMNs remain controversial because preoperative identification of malignancy is often difficult. Mixed-type IPMNs are thought to be an advanced form of branch duct IPMNs, but this subtype has not yet been clearly defined [4, 5] . Many of the previous studies on IPMNs were performed without properly defining or classifying these neoplasms. In addition, one pitfall in the classification is that many of the branch duct IPMNs have some degree of involvement in the main duct, as seen by histologic examinations, resulting in many branch duct IPMNs being diagnosed preoperatively as in the mixed category. In practice, therefore, the clinical classification should be done morphologically based on preoperative imaging findings [4] .
Factors that predicted malignancy of IPMNs in previous studies were main duct type [12] [13] [14] [15] , main pancreatic duct dilatation, mural nodules, tumor size [10, 12, 14, 15] , dilated papilla of Vater leaking mucin [15] , symptoms [14, 15] , jaundice [13] , and diabetes [12] . With respect to morphologic features, Matsumoto et al. [9] reported that IPMNs with a diameter \30 mm and/or without mural nodules were all benign. Similarly, Sugiyama et al. [10] found that a tumor [30 mm and/or the presence of mural nodules were significant predictors of malignancy by multivariate analysis.
The aim of the present study was to define the clinicopathologic characteristics, imaging findings, and long-term outcome of patients with IPMNs who underwent resection at our institution. Another purpose was to determine the factors correlated with malignancy, which included CIS and invasive carcinoma of the branch duct and mixed-type IPMNs, that we could utilize to determne the indications for surgical resection of these neoplasms.
Patients and methods
A total of 72 consecutive patients with IPMNs who underwent surgical resection between January 1984 and May 2006 at Kyoto University Hospital were reviewed. The diagnosis of IPMN was confirmed histologically by at least two pathologists who examined the resected tissues. IPMNs were distinguished from mucinous cystic neoplasms (MCNs) by the absence of the ovarian-type stroma that is characteristic of the latter neoplasms and by the various well known clinical features [5] .
Based on preoperative imaging findings, the IPMNs were classified into three morphologic subtypes: main duct IPMNs, branch duct IPMNs and mixed-type IPMNs. Lesions that predominantly involved the main duct were classified as main duct IPMNs, and lesions that involved a branch duct were classified as branch duct IPMNs. Lesions with involvement of not only a branch duct but also the main duct, with the former being predominantly affected, were classified as mixed-type IPMNs.
The lesions were histologically graded as adenoma, borderline neoplasm, CIS, or invasive carcinoma according to the WHO classification of IPMNs [3] . The first three categories were defined as noninvasive IPMNs. Survival between patients with noninvasive IPMNs and those with invasive IPMNs were compared. Survival between patients with invasive IPMNs and patients with pancreatic ductal carcinomas matched for the UICC stage [16] and the surgical era were also compared.
The clinical characteristics studied were the demographic data, the location of the neoplasm, and presenting symptoms (jaundice, abdominal pain, back pain, fever, loss of weight, a history of pancreatitis, onset or worsening of diabetes). The surgical procedure, postoperative complications, morbidity, and mortality were also investigated. Follow-up information was obtained from medical records or by direct contact with patients or their referring physicians.
Patients with neoplasms located in the head, neck, or uncinate process of the pancreas usually underwent pyloruspreserving pancreatoduodenectomy (PPPD) or pancreatoduodenectomy (PD), whereas patients with neoplasms in the body and/or tail of the pancreas underwent distal pancreatectomy (including spleen-preserving resection). Total pancreatectomy was performed for main duct IPMNs with diffuse involvement or for multiple branch duct IPMNs. Partial resection or middle segmental pancreatectomy was performed in the patients with small branch duct lesions. Peripancreatic lymph nodes were dissected in all patients. In the patients with suspected lymph node metastasis or invasive IPMN diagnosed preoperatively or intraoperatively, extended lymph node dissection was performed with the aim of eradicating residual cancer cells. Intraoperative frozen section examination of the pancreatic surgical margins was performed routinely. The margin was defined as positive if the duct epithelium showed moderate dysplasia or more advanced changes. In the patients with positive margins, additional resection was continued until a negative result was obtained.
The analysis of the patients with branch duct and mixedtype IPMNs was done to determine the clinical factors correlated with malignancy and thus define the indications for resection. Because mixed-type IPMN is thought to represent an advanced form of branch duct IPMNs [4, 5] , branch duct and mixed lesions were combined as branch duct-mixed IPMNs in this analysis. The branch duct-mixed IPMNs were classified as benign (adenoma and borderline neoplasm) or malignant (CIS and invasive carcinoma), and their characteristics were compared to identify predictors of malignancy.
In addition to the above-mentioned clinical characteristics, the following factors were investigated: duration of symptoms, history of alcohol intake and smoking, serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), imaging findings (including the factors mentioned below), and pancreatic juice cytology. Imaging findings-including the diameter of cystic lesions, the diameter of the main pancreatic duct (MPD), the presence of mural nodules, and mucin secretion from a dilated papilla of Vater-were determined by a combination of abdominal ultrasonography (US), computed tomography (CT), endoscopic retrograde cholangiopancreatography (ERCP), magnetic resonance cholangiopancreatography (MRCP), and endoscopic ultrasonography (EUS). When [
18 F] fluorodeoxyglucose (FDG)-positron emission tomography (PET) was performed, FDG uptake was quantified; a standardized uptake value (SUV) [ 2.2 was defined as indicating accumulation of the tracer [17] . Pancreatic juice for cytology was obtained during ERCP.
Statistical analysis
Continuous variables are presented as the median and range. Comparison between groups was performed by the Mann-Whitney U-test, and categorical variables were compared by the v 2 test. Multivariate logistic regression analysis was also performed. Survival curves were drawn by the Kaplan-Meier method and were compared by the log-rank test. For all analyses, p \ 0.05 was considered statistically significant.
Results

Clinical and histologic characteristics
Clinical and histologic characteristics of the 72 patients with IPMN are shown in Table 1 . Fifteen patients had main duct IPMNs, 49 patients had branch duct IPMNs, and 8 patients had mixed-type IPMNs. In total, all of the main duct IPMNs were malignant, and 10 of these patients had invasive carcinoma; 29 patients with branch duct and mixed-type IPMNs were malignant, including invasive carcinoma in 18 patients with branch duct IPMNs and 2 patients with mixed-type IPMNs. Operative procedures and postoperative complications
In terms of the operations done, PPPD was performed in 29 patients, and the other procedures were PD in 8 patients, distal pancreatectomy in 20 patients (including one patient with spleen-preserving distal pancreatectomy), total pancreatectomy in 10 patients, partial resection of the pancreas in 4 patients, and middle segmental pancreatectomy in 1 patient. The postoperative morbidity rate was 25%, but there were no severe complications that needed further surgical intervention or intensive care (Table 2 ). There were no deaths related to surgery in this series.
Survival rate and recurrence rate
The mean postoperative follow-up period was 54 months (range 1-267 months). The overall survival rate of patients with main duct IPMNs was significantly lower than that of those with other subtypes (Fig. 1) . The overall 5-year and 10-year survival rates of patients with main duct IPMN were 66.7% and 17.8%, respectively. Patients with noninvasive main duct IPMNs (n = 5) did not suffer from recurrence and did not die of pancreatic disease, but two patients died of other diseases at more than 5 years after resection (one patient died of esophageal cancer at 62 months after resection, and the other died of liver cirrhosis at 117 months. On the other hand, 6 of 10 patients with invasive main duct IPMNs died of recurrence, including one patient with liver metastasis at the initial operation; another patient died of some other disease (pneumonia at 110 months). Recurrence was local in three patients, and the bone and peritoneum were involved in one patient each.
The 5-year overall survival rate of patients with invasive branch duct-mixed IPMNs (n = 20) was 58.4%, which was significantly lower than that of patients with noninvasive branch duct/mixed-type IPMNs (p = 0.0003) (Fig. 2) . None of the patients with noninvasive branch duct/mixedtype IPMNs (n = 37) had recurrence, and their 10-year overall survival rate was 100%. In contrast, six patients with invasive branch duct/mixed-type IPMN died, with the cause of death being recurrence in four patients (local recurrence in two patients, peritoneal dissemination in one patient, and unknown in one patient) and other diseases in two patients (unknown disease in one patient and bile duct GI: gastrointestinal Fig. 1 Overall survival of patients with main duct (n = 15), branch duct (n = 49), and mixed-type (n = 8) intraductal papillary mucinous neoplasms (IPMNs). The 5-year survival rates for main duct, branch duct, and mixed-type IPMNs were 66.7%, 83.6%, and 100%, respectively. The survival of patients with main duct IPMNs was significantly worse than that of the other patients Fig. 2 Overall survival of patients with invasive branch duct/mixedtype IPMNs (n = 37) and noninvasive IPMNs (n = 20). The overall survival rate of patients with branch duct/mixed-type IPMNs was significantly lower than that of patients with noninvasive IPMNs (p = 0.0003). No patient from the latter group died carcinoma in one patient). Two other patients with local recurrence are alive at 30 months and 39 months after surgery, respectively. A comparison between invasive and noninvasive IPMNs of all subtypes is shown in Figure 3 . The survival rate of patients with noninvasive IPMNs (n = 42) was excellent, and the overall 5-and 10-year survival rates were 100% and 78.1%, respectively. In contrast, the overall 5-and 10-year survival rates of patients with invasive IPMNs (n = 30) were 57.6% and 43.2%, respectively, which were significantly lower than those for noninvasive IPMNs (p = 0.0002) but higher than those of matched patients with ductal carcinoma (p = 0.0004).
Clinical predictors of malignancy for branch duct and mixed-type IPMNs
A total of 49 patients with branch duct IPMNs and 8 patients with mixed-type IPMNs were combined into a single group of branch duct-mixed IPMNs. These 57 patients comprised 28 with benign neoplasms and 29 with malignant neoplasms. The clinical characteristics of the benign and malignant groups are compared in Table 3 .
There were no significant differences of age and sex between the benign and malignant groups. Six clinical factors-abdominal pain, weight loss, serum CA19-9 levels, MPD diameter, diameter of cystic lesions, presence of mural nodules-showed a significant correlation with malignancy by univariate analysis (Table 3 ). The mean duration of symptoms was not different between the two groups, and habitual alcohol intake and a history of smoking were generally similar in the two groups.
Serum CEA and CA19-9 levels were measured in 40 patients (18 in the benign group, 22 in the malignant group) and 49 patients (24 in the benign group, 25 in the malignant), respectively. All patients underwent transabdominal US. CT was done in 56 patients, and the other imaging modalities were ERCP in 52 patients, MRCP in 40 patients, and EUS in 45 patients. The presence or absence of mucin and a dilated papilla of Vater were determined in 38 and 37 patients, respectively, by ERCP and/or duodenoscopy. Pancreatic juice cytology was investigated in 19 patients and FDG-PET was performed in 28 patients. CA19-9 levels, which had a significant correlation with malignancy by univariate analysis, showed a wide range in the malignant group and exceeded 100 U/ml in seven patients, wheeas only one patient from the benign group had such a high level.
Mucin and dilation of the papilla of Vater were observed in about 40% of the patients even in the benign group. The specificity and sensitivity of pancreatic juice cytology for the malignant group were 90% and 44%, respectively. The specificity and sensitivity of FDG-PET for malignant group were 57% and 64%, respectively.
When multivariate analysis of the above factors was performed, the diameter of cystic lesions was the only independent predictor of malignancy that was identified ( Table 4) .
The relation between the diameter of cystic lesions and the presence of mural nodules was further investigated in the benign and malignant groups (Fig. 4) . Although the presence of mural nodules was correlated with malignancy by univariate analysis (Table 3 ) and the diameter of cystic lesions was the only independent predictor on multivariate analysis (Table 4) , 10 patients from the benign group had mural nodules and 4 patients who had cystic lesions \30 mm in diameter and no mural nodules were found to have malignant IPMNs (including three patients with CIS and one patient with invasive carcinoma). Moreover, two of these patients were asymptomatic.
Discussion
Since the first report by Ohashi et al. [1] in 1982, IPMNs have been recognized with increasing frequency. This neoplasm features a broad spectrum of histologic abnormalities that range from adenoma to invasive carcinoma [4] . The only definitive treatment for IPMNs is surgical resection, and complete resection of noninvasive IPMNs (adenoma, borderline neoplasms, CIS) achieves an excellent survival rate [6] [7] [8] . On the other hand, the survival rate of patients with invasive IPMNs is significantly lower than Fig. 3 Overall survival of patients with invasive IPMNs (n = 30), noninvasive IPMNs (n = 42), and pancreatic ductal carcinoma (n = 30) matched for tumor stage and surgical era. The survival rate of patients with noninvasive IPMNs was excellent. The 5-year survival rate of patients with invasive IPMNs was 57.6%, which was significantly lower than that of patients with noninvasive IPMNs (p = 0.0002) but better than that of matched patients with pancreatic ductal carcinoma (p =
that of patients without invasive cancer. However, there is no current consensus as to whether invasive IPMNs have a poor prognosis similar to that of pancreatic ductal carcinomas. In our series, 42 patients with noninvasive IPMNs did not suffer from recurrence or die of their disease after resection and showed excellent survival. In contrast, the 5-year survival rate of patients with invasive IPMNs was only 57.6%, which was significantly lower than that of patients with noninvasive IPMNs (p = 0.0002), although it was better than that of ductal carcinoma patients matched for the UICC stage [16] and the surgical era. IPMNs are classified as main duct, branch duct, and mixed-type IPMNs [4, 5] . Because there are significant differences in the frequency of malignancy and other clinical characteristics between main duct and branch duct IPMNs, these two types should be distinguished preoperatively based on imaging findings to allow appropriate clinical management. However, there are still some ambiguities related to this morphologic classification [4, 5] . In many previous studies of IPMNs, analyses were done without proper definition or classification of the neoplasms. In this study, all of the neoplasms were preoperatively classified according to the above-mentioned definitions. There is general agreement that main duct IPMNs should be resected if the patient is a suitable candidate for surgery because of the high risk of malignancy [5] . In our series, all of the main duct IPMNs were malignant, and these patients had a significantly lower survival rate than those with other subtypes. Although the patients with main duct IPMNs comprised 21% of our series, similar to the percentage reported in the previous studies [7, 10, 18] , the reason for the high malignancy rate associated with main duct IPMNs is unknown. However, resection of main duct IPMNs seems to be a reasonable approach to treatment.
The indications for resection of branch duct and mixedtype IPMNs remain controversial because malignancy is less common than in main duct IPMNs and the preoperative detection of malignancy is often difficult. Therefore, we focused on identifying factors that could be used to predict malignancy of branch duct and mixed-type IPMNs. As a result, we identified abdominal pain, weight loss, serum CA19-9 levels, MPD diameter, the diameter of cystic lesions, and the presence of mural nodules as factors significantly associated with malignancy on univariate analysis. However, the diameter of cystic lesions was the only independent predictor of malignancy on multivariate analysis. Other factors, such as a tumor marker (CEA), mucin leaking from a dilated papilla, pancreatic juice cytology, and accumulation on FDG-PET, showed no significance as predictors of malignancy.
Preoperative evaluation of IPMNs by various imaging modalities (e.g., US, CT, EUS, ERCP, MRCP) is essential before making a decision about treatment. EUS has been reported to be the most useful modality for detecting mural nodules, with an accuracy of 92.3%-100% [14, 19] . However, demonstration of mural nodules is often difficult even with EUS, and one reason may be the difficulty of differentiating nodules from mucin plugs. Another problem is that the diagnostic accuracy of EUS depends on the operator's technique and experience. On the other hand, the diameter of cystic lesions (the only independent predictor of malignancy in our multivariate analysis) can be objectively determined by EUS or other conventional imaging modalities such as abdominal US and CT. Therefore, determining the malignancy of branch duct and mixed-type IPMNs based on the diameter of cystic lesions may be a practical approach.
In the international guidelines [5] , positive symptoms and cysts [30 mm in size are described as important for predicting the malignancy of branch duct IPMNs. Matsumoto et al. [9] and Sugiyama et al. [10] reported that a tumor\30 mm and the absence of mural nodules suggested benign disease in patients with branch duct IPMNs. Therefore, the guidelines [5] state that asymptomatic patients with small branch duct IPMNs may be managed by careful follow-up. However, our series of 57 patients with branch duct and mixed-type IPMNs included four patients who had cystic lesions \30 mm in diameter without mural nodules that were malignant, and two of these patients were asymptomatic.
These results indicate that predicting malignancy based on symptoms, mural nodules, and the cysts diameter is generally correct although not always accurate. In other words, we have to keep in mind that none of these factors can precisely predict malignancy.
It is quite important for surgical resection, which is the only curative treatment for IPMNs, to achieve excellent survival before the neoplasm becomes invasive [6] [7] [8] . It should be emphasized that pancreatic resection has now become a feasible procedure that is performed safely at hospitals with a sufficient case load [20, 21] . In our series, there were no deaths and no severe complications after surgery.
Conclusions
Our conclusion about the surgical indications for branch duct and mixed type IPMNs is as follows: Given the difficulty of predicting malignancy and the unsatisfactory survival of patients with invasive components, these lesions should be managed by aggressive resection at highvolume hospitals before invasion occurs. This strategy should result in improved survival of patients with IPMNs. Of course, all clinical management should be decided by taking into consideration the patient's wishes and after obtaining informed consent.
